These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33911759)

  • 1. Effect of Weight Reduction on Treatment Outcomes for Patients with Atopic Dermatitis.
    Jung MJ; Kim HR; Kang SY; Kim HO; Chung BY; Park CW
    Ann Dermatol; 2020 Aug; 32(4):319-326. PubMed ID: 33911759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk factors for food allergy in infants with atopic dermatitis.
    Akelma Z; Köse SŞ; Özmen S
    Turk J Pediatr; 2023; 65(2):235-244. PubMed ID: 37114689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipokines as Biomarkers of Atopic Dermatitis in Adults.
    Jaworek AK; Szepietowski JC; Szafraniec K; Jaworek M; Hałubiec P; Wojas-Pelc A; Pokorski M
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implication of Serum Adiponectin Levels in Adult Patients with Atopic Dermatitis.
    Lee SH; Bae Y; Park YL
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
    Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of adipokine to insulin sensitivity and glycemic regulation in obese women--the effect of body weight reduction by caloric restriction.
    Golubović MV; Dimić D; Antić S; Radenković S; Djindjić B; Jovanović M
    Vojnosanit Pregl; 2013 Mar; 70(3):284-91. PubMed ID: 23607240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.
    Hagino T; Saeki H; Kanda N
    J Dermatol; 2022 Nov; 49(11):1158-1167. PubMed ID: 35986480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatol; 2023 Jul; 50(7):869-879. PubMed ID: 36890685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
    Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
    Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of acupressure on pruritus and lichenification associated with atopic dermatitis: a pilot trial.
    Lee KC; Keyes A; Hensley JR; Gordon JR; Kwasny MJ; West DP; Lio PA
    Acupunct Med; 2012 Mar; 30(1):8-11. PubMed ID: 22207450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
    Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
    Br J Dermatol; 2021 May; 184(5):888-895. PubMed ID: 32959390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.